Harbour BioMed Reports 2025 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its interim results for the six months ended June 30, 2025. Dr. Jingsong Wang, Founder,...
XtalPi Holdings Announces 2025 Interim Results
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: Revenue surged 404% year over year to RMB 517 million in the first half of 2025. Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. XtalPi was added to the MSCI China Small...
Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0
Start Your Journey to Access Vast Chemical Space CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Developing new medicines demands smart technology and powerful tools. DNA-encoded library (DEL) technology, with its unique ability to rapidly screen billions of compounds to identify small molecule hits, has transformed drug discovery. HitGen Inc. is raising the bar...
Neusoft Medical Systems Launches China’s First Photon-Counting CT with NMPA Approval
SHENYANG, China, Aug. 27, 2025 /PRNewswire/ -- Neusoft Medical Systems today announced that its NeuViz P10 photon-counting CT has received market approval from China's National Medical Products Administration (NMPA). This marks the first photon‑counting CT approved in China, and the world's first wide‑body system equipped with an 8‑cm detector. Neusoft Medical Systems Launches China’s First Photon-Counting CT...
NUHS SPEARHEADS AI-POWERED BRAIN CARE PROGRAMME TO TACKLE UNDERDIAGNOSIS AND IMPROVE PREVENTION OF DEMENTIA
Novel initiative in Asia integrates predictive AI with personalised health coaching to empower early action and prevention SINGAPORE, Aug. 27, 2025 /PRNewswire/ -- Dementia remains a hidden epidemic in Singapore, with slightly more than half of all cases going undiagnosed. According to the Well-being of the Singapore Elderly (WiSE) 2023 study, 51.5 per...
NYSE Content Advisory: Pre-Market update + Wall Street braces for Nvidia’s earnings
NEW YORK, Aug. 27, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market update + Wall Street braces for Nvidia’s earnings...
Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states
Phase 2b/3 Alzheimer's trial enrolment passes 50% - twenty US trial sites continuing to recruit participants SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and without food,...
Innovent Announces 2025 Interim Results and Business Updates
Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China, Aug. 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology...
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its core product, Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®. The drug generated net sales of approximately RMB 170 million. Keymed...
Digital twin technology with AI to boost efficiency and reliability in pharmaceutical manufacturing
Cambridge Advanced Research and Education in Singapore (CARES), the University of Cambridge's first overseas research centre, together with the A*STAR Institute for Infocomm Research (A*STAR I2R) has developed a digital twin platform that uses artificial intelligence (AI) and real-time plant data to enhance fault detection, system monitoring, and predictive maintenance in...














